GlassScriptPhysician profile
Sean P Groark
NPI 1235109737
$5,685.68
in general payments reported to CMS, 2019-2025
21 companies · $1,883 in 2025
The $1,883 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $165 · 2021: $1,763 · 2022: $526 · 2023: $300 · 2024: $308 · 2025: $1,883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,379 · Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,378.83 |
| Food and Beverage | $1,112.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,082.59 | 2021-2025 | Triclip, Gallant, Aveir |
| Edwards Lifesciences Corporation | $1,226.84 | 2021-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novartis Pharmaceuticals Corporation | $625.65 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $361.68 | 2019-2023 | Xarelto |
| Pfizer INC. | $230.34 | 2019-2025 | |
| Medtronic, INC. | $196.20 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $170.84 | 2022-2024 | Camzyos |
| Sanofi-Aventis U.S. LLC | $145.65 | 2019-2024 | |
| Amgen INC. | $136.17 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.19 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $92.11 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $64.56 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $54.55 | 2019 | |
| Heartflow, INC. | $46.54 | 2025 | |
| Boston Scientific Corporation | $32.88 | 2020-2023 | Watchman Access System |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $28.82 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.17 | 2025 | Lifevest |
| Kiniksa Pharmaceuticals International, Plc | $21.76 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $20.83 | 2021 | |
| Siemens Medical Solutions USA, INC. | $17.20 | 2019 | |
| Chiesi USA, INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Groark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.